by University of California, Los Angeles Researchers from the UCLA Jonsson Comprehensive Cancer Center and other institutions in the U.S., Canada, the United Kingdom and Singapore, have identified 1,178 biomarkers in men’s genomes—the complete set of genetic material inherited from one’s parents—that predict how an individual person’s prostate cancer will grow. The finding suggests that...
Tag: <span>Prostate cancer</span>
Post
Long-term hormone tx increases mortality risk for men with low PSA after prostate surgery
Analysis finds PSA levels predict which men with recurrent prostate cancer will be harmed by adding long-term hormone therapy to radiation AMERICAN SOCIETY FOR RADIATION ONCOLOGY CHICAGO, September 15, 2019 — A secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer finds long-term hormone therapy does more harm than good for many men and...
Post
Hormone Therapy for Prostate Cancer May Raise Risk of Alzheimer’s, Dementia
Posted Today For patients with prostate cancer, treating the disease with androgen deprivation therapy (ADT) is linked to a higher likelihood of being diagnosed with Alzheimer’s disease or dementia, compared to patients who do not receive the therapy, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania. The results were published in JAMA. Of the...
Post
Prostate cancer urine test shows who needs treatment and when
by University of East Anglia Researchers at the University of East Anglia and the Norfolk and Norwich University Hospital have developed a urine testto diagnose aggressive prostate cancer and predict whether patients will require treatment up to five years earlier than standard clinical methods. The experimental new test called ‘PUR’ (Prostate Urine Risk) also identifies men who are up to eight times less likely to need treatment within five...
Post
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer
DANA-FARBER CANCER INSTITUTE After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care. Chicago – Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute’s Lank Center for...
Post
Enzyme PHLPP2 could be a viable drug target for treating prostate cancer
COLD SPRING HARBOR LABORATORY Cold Spring Harbor, NY — An estimated 450,000 Americans are diagnosed each year with a cancer that’s driven by MYC, an oncogene that hijacks growth and metabolism in cancer cells. MYC has a storied past of being notoriously hard for researchers to directly disable. “Now, we have a new way of getting at this old...
Post
Fingerprick PSA Test Has In-Office Results in 12 Minutes
First of Its Kind Approved by FDA Instead of waiting days or even weeks for the result of a prostate-specific antigen (PSA) test, physicians and their patients can now have the information in minutes, thanks to a novel device recently approved by the US Food and Drug Administration. The Sangia Total PSA Test (OPKO Diagnostics) is the first test that can provide PSA results at the point of...
Post
Testosterone slows prostate cancer recurrence in low-risk patients
In the largest such study so far undertaken, US researchers have shown that testosterone replacement slows the recurrence of prostate cancer in low-risk patients. This may call into question the general applicability of Nobel-Prize winning hormonal prostate treatment. The work is presented at the European Association of Urology congress in Barcelona. Doctors have long regarded testosterone as a hormone which promotes prostate cancer. The 1941 work of Huggins and Hodges won Huggins...
Post
Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells
Abstract Emerging evidence links exosomes to cancer progression by the trafficking of oncogenic factors and neoplastic reprogramming of stem cells. This necessitates identification and integration of functionally validated exosome-targeting therapeutics into current cancer management regimens. We employed quantitative high throughput screen on two libraries to identify exosome-targeting drugs; a commercially available collection of 1280 pharmacologically...
Post
Low-dose aspirin does not cut death from prostate cancer
Charlotte Skriver, from the Danish Cancer Society Research Center in Copenhagen, and colleagues used a nationwide data registry to assess the association between postdiagnosis use of low-dose aspirin (at least two prescriptions [75 to 150 mg] filled within one year after prostate cancer diagnosis) and prostate cancer mortality. The authors note that 29,136 patients were diagnosed from 2000 through 2011. During a median of 4.9 years...